Sells cancer medicines, including CABOMETYX and COMETRIQ, through specialty distributors and pharmacies, and develops additional cancer treatments.
10-K for FY2025, filed Feb 10, 2026Sales related to cabozantinib account for the majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases…View ↗
Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and regimens at the forefront of…View ↗
Our commercial products, CABOMETYX and COMETRIQ, are sold initially through wholesale distribution and specialty pharmacy channels and…View ↗
Specialty distributors and specialty pharmacy providers buy Exelixis products and resell them to health care providers and patients. Outside the U.S., Ipsen and Takeda handle commercialization and distribution of CABOMETYX, while Ipsen handles COMETRIQ.
10-K for FY2025, filed Feb 10, 2026
10-K for FY2025, filed Feb 10, 2026
Year Ended December 31, 2025 2024 2023 Affiliates of Cencora, Inc. 22% 18 % 17 % Affiliates of McKesson Corporation 19% 16 % 17 %…View ↗
Yes. It kept 34 cents of every revenue dollar as net income in FY2025 and turned 38 cents into free cash flow.
10-Q for Q3 FY2026, filed Oct 29, 2026
$218.1MView ↗
10-Q for Q3 FY2026, filed Oct 29, 2026
Open tableView ↗
Additional cancer indications
The latest report includes CABOMETYX for previously treated pancreatic and extra-pancreatic neuroendocrine tumors; the older report listed renal, liver, differentiated thyroid and medullary thyroid cancers.
10-K for FY2022, filed Feb 7, 2023 10-K for FY2025, filed Feb 10, 2026Sales related to cabozantinib account for the majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including…View ↗
Zanzalintinib advances
Zanzalintinib has moved from a clinical-stage pipeline asset to an FDA-reviewed candidate for certain colorectal cancers, with a late-stage development program in other indications.
10-K for FY2022, filed Feb 7, 2023 10-K for FY2025, filed Feb 10, 2026The year 2022 was our sixth year of annual profitability, which featured growth in net product revenues of approximately 30% year-over-year…View ↗
Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and regimens at the forefront of…View ↗
Competes with Merck &, Pfizer, BMS, Eisai, Novartis, Bayer, Blueprint Medicine, Roche, Eli Lilly, Lantheus Holdings, POINT Biopharma, Curium US, ITM Solucin, and Genzyme
10-K for FY2025, filed Feb 10, 2026CABOMETYX - RCC: We believe the principal competition for CABOMETYX in advanced RCC includes: the combination of Merck & Co.’s…View ↗
Loading...